Suspended

VASSPRVasopressin for Septic Shock Pragmatic Trial

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Vasopressin

+ Recommendation to use a higher initiation threshold for vasopressin

+ Recommendation to use a lower initiation threshold for vasopressin

DrugOther
Who is being recruted

Urogenital Diseases+14

+ Diabetes Insipidus

+ Endocrine System Diseases

Over 18 Years
+3 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 4
Interventional
Study Start: February 2024
See protocol details

Summary

Principal SponsorIntermountain Health Care, Inc.
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: February 1, 2024

Actual date on which the first participant was enrolled.

Septic shock is a dangerous condition where severely low blood pressure results from a serious infection. Treating septic shock usually involves medications called vasopressors that help raise blood pressure. In some cases, the initial vasopressor medications may not work well enough, leading doctors to add another medication called vasopressin. However, it is not clear at what point this additional medication should be started. This study is important because it aims to compare two strategies for using vasopressin in treating septic shock, helping to determine the best approach to improve patient outcomes. In this study, participants will be treated with standard first-line vasopressors and then, based on the strategy being tested, vasopressin will be added either at a lower or higher threshold of blood pressure. The trial is designed to compare these two approaches by seeing which one better supports blood pressure in septic shock patients. Although the trial does not specify risks or benefits, understanding the optimal timing for adding vasopressin could lead to better treatment protocols and potentially improve survival rates for those with septic shock.

Official TitleVasopressin for Septic Shock Pragmatic Trial
Principal SponsorIntermountain Health Care, Inc.
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

2050 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.


Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesDiabetes InsipidusEndocrine System DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsInfectionsInflammationKidney DiseasesPathologic ProcessesPituitary DiseasesShockShock, SepticPathological Conditions, Signs and SymptomsUrologic DiseasesSystemic Inflammatory Response SyndromeSepsisFemale Urogenital DiseasesMale Urogenital Diseases

Criteria

3 inclusion criteria required to participate
Age ≥18 years

Admitted to a study hospital emergency department (ED) or inpatient care unit

Administration of vasopressor(s) for septic shock

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Active Comparator
Recommended strategy for treatment of septic shock includes initiation of fixed-dose IV vasopressin (1.8 units/hour) as a second-line vasopressor if the combined norepinephrine-equivalent dose of other vasopressors reaches ≥0.4 mcg/kg/min. Use of the recommended treatment strategy (via entry of an order for threshold-based vasopressin initiation) or an alternative treatment strategy is at the discretion of patients' treating clinical team.

Group II

Active Comparator
Recommended strategy for treatment of septic shock includes initiation of fixed-dose IV vasopressin (1.8 units/hour) as a second-line vasopressor if the combined norepinephrine-equivalent dose of other vasopressors reaches ≥0.1 micrograms/kilogram/minute (mcg/kg/min). Use of the recommended treatment strategy (via entry of an order for threshold-based vasopressin initiation) or an alternative treatment strategy is at the discretion of patients' treating clinical team.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 13 locations

Suspended

Cassia Regional Hospital

Burley, United StatesOpen Cassia Regional Hospital in Google Maps
Suspended

American Fork Hospital

American Fork, United States
Suspended

Cedar City Hospital

Cedar City, United States
Suspended

Layton Hospital

Layton, United States
Suspended13 Study Centers